‘Many States have evinced interest in Sputnik V’

Dr. Reddy’s received 1.50 lakh doses from Russia on May 1 and 60,000 second dose component on Sunday

May 17, 2021 10:47 pm | Updated 10:48 pm IST - HYDERABAD

HYDERABAD, TELANGANA: 17/05/2021: A medical specialist holds a vial of Sputnik V vaccine against the Covid-19 coronavirus vaccine during the launch of its first phase programme at Apollo Hospital in Hyderabad on Monday, May 17, 2021. Photo: NAGARA GOPAL / The Hindu

HYDERABAD, TELANGANA: 17/05/2021: A medical specialist holds a vial of Sputnik V vaccine against the Covid-19 coronavirus vaccine during the launch of its first phase programme at Apollo Hospital in Hyderabad on Monday, May 17, 2021. Photo: NAGARA GOPAL / The Hindu

Many States have approached Dr. Reddy’s Laboratories, marketing partner for Sputnik V in India, to procure the Russian vaccine, a member of the company’s management team said on Monday.

Their interest assumes significance in the backdrop of the vaccination programme in the country slowing down due a shortage of vaccines and more people becoming eligible with the Centre earlier this month permitting vaccination of those above 18 years of age.

“As of now, 8-9 States have approached,” Global Head of Integrated Product Development Organisation Sauri Gudlavalleti said at the launch of a pilot programme for the vaccine at Apollo Hospitals here on Monday.

Last week, announcing the roll-out of the two-dose vaccine, Dr. Reddy’s said the MRP per dose was ₹995.40, which includes a 5% GST. The company had received the first consignment of 1.50 lakh doses from Russia on May 1 and 60,000 doses of the second dose component of the vaccine on Sunday.

The cost is expected to come down with the commencement of domestic production. Six companies have entered into agreements to produce 850 million doses a year, and the made in India Sputnik is expected to be launched by July. “Some have started making small batches, which can be used for [regulatory] submission purposes,” Mr. Gudlavalleti said.

The rule stipulating that vaccine-makers set aside 50% of the production for the Centre would kick in with domestic production. For now, Dr. Reddy’s intends to take the imported vaccine primarily to private hospitals in 35 cities. “We are working diligently to detail out our ability to supply to the government. The quantity [of vaccines] we are sitting on right now is limited,” he said. It is expecting 36 million doses (for 18 million people) from Russia over the next two months.

On the price, he said “current imported stock is going to be single price for all... when domestic production comes it will be [priced] as per the regulations in each channel.” The Centre has been procuring Covaxin and Covishield, the other two vaccines, at the rate of ₹150 per dose.

To queries on plans to bring Sputnik Light, a single dose vaccine launched by Sputnik V developers, he said the data forming the basis for its approval in Russia was being studied. It was expected to be submitted to the regulator in India in the next few weeks.

President – Hospitals Division of Apollo Hospitals Enterprises, Dr. K. Hari Prasad, said the pilot phase would allow Dr. Reddy’s and Apollo to test the arrangements and cold chain logistics, since Sputnik had to be stored at minus 18 degrees C, and prepare for the launch. “We are doing a trial run from today to fix any logistics issues and to prove that they are safe, by vaccinating around 50,000 staff and families of Dr. Reddy’s, across the country. The cost will be ₹1,200-₹1,250, including vaccination and vaccine administering,” he said.

A pilot programme is to be launched next in Visakhapatnam and extended to Delhi, Mumbai, Bangalore, Ahmedabad, Chennai, Kolkata, and Pune, a release said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.